宋家纶先生在担任公司财务总监期间，勤勉、忠实地履行了相关职责和义务， 公司及董事会对宋家纶先生表示衷心感谢！ 证券代码：000597 证券简称：东北制药 公告编号：2024-071 东北制药集团股份有限公司 关于公司财务总监辞职暨聘任财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、财务总监辞职情况 东北制药集团股份有限公司（以下简称"公司"）董事会近日收到公司财务 总监宋家纶先生的书面辞职报告，宋家纶先生因工作安排原因申请辞去公司财务 总监职务。根据《公司法》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等法律法规及《公司章程》的有关规定，宋家纶先生的 辞职自辞职报告送达公司董事会之日起生效。 截至本公告披露日，宋家纶先生持有公司股份 320,000 股。辞去公司财务总 监职务后，宋家纶先生所持股份将继续按照《上市公司董事、监事和高级管理人 员所持本公司股份及其变动管理规则》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人 员减持股份》等相关规定进行 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，东北制药集团股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的《化学原料药上市申请批准通知书》（登记号：Y20230000623， 受理号：CYHS2360562，通知书编号：2024YS01308），现就相关情况公告如下： 二、其他相关信息 恩格列净是一种钠葡萄糖共转运体 2(SGLT-2)抑制剂，通过减少肾脏的葡萄 糖重吸收，降低肾糖阈，促进葡萄糖从尿液排出。恩格列净还可减少钠重吸收， 增加钠向远端小管的转运。其制剂临床用于治疗 2 型糖尿病、心力衰竭和慢性肾 脏病。 与传统降糖药物相比，恩格列净有着更优良的降糖效果、更稳定的代谢特点 以及更好的联合协同作用。长期服用可以起到保护胰岛β细胞功能、控制血压和 1 化学原料药名称 通用名称：恩格列净 英文名/拉丁名：Empagliflozin 化学原料药注册 标准编号 YBY75242024 有效期 18 个月 包装规格 5kg/箱 申请事项 境内生产化学原料药上市申请 审批结论 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-068 东北制药集团股份有限公司 关于子公司涉及诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、诉讼事项受理的基本情况 近日，东北制药集团股份有限公司（以下简称"东北制药/公司"）子公司沈 阳东瑞精细化工有限公司（以下简称"东瑞公司"）收到沈阳经济技术开发区人 民法院（以下简称"经开区法院/本院"）民事判决书，谭敏娟、苏锋、徐素珍、 杨井强、世恒谦、闫明福、张玲、王怀信、肖强 9 名自然人向经开区法院起诉东 瑞公司股权纠纷案件进行了审理并作出判决。 现将有关事项公告如下： （一）沈阳经济技术开发区人民法院民事判决书（2023）辽 0191 民初 8715 号 原告：谭敏娟 被告：东瑞公司 原告向经开区法院提出诉讼请求： 1.请求依法判令被告以 11,452,478.76 元价格回购原告持有的 3%股权； 2.本案诉讼费由被告承担。 庭审过程中原告变更第一项诉讼请求为：请求经开区法院依法判令被告以 12,102,353.34 元价格回购原告持有的 3%股权。 经审理，判决如下： 被 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-067 东北制药集团股份有限公司关于控股股东一致行动人 增持公司股份计划暨取得金融机构贷款承诺函的公告 公司控股股东一致行动人江西方大钢铁集团有限公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1.东北制药集团股份有限公司（以下简称"东北制药/公司"）控股股东辽宁 方大集团实业有限公司（简称"方大集团"）一致行动人江西方大钢铁集团有限 公司（以下简称"方大钢铁/增持主体"）计划自本公告披露之日起 6 个月内增持 公司股份，计划增持金额不少于人民币 7,500 万元,不超过人民币 15,000 万元。 2.方大钢铁将基于对公司股票价格的合理判断，并根据公司股价波动情况及 资本市场整体趋势，择机实施增持计划。 3.根据《上市公司收购管理办法》的相关规定，本次增持计划不触及要约收 购，不会导致公司股权分布不符合上市条件，不会导致公司控制权发生变化。 1.增持主体名称：江西方大钢铁集团有限公司 2.增持主体已持有公司股份数量及比例：公司 ...

Company Update - Northeast Pharmaceutical's controlling shareholder, Fangda Group, through its affiliate Jiangxi Fangda Iron and Steel Group Co Ltd (Fangda Iron and Steel), plans to increase its shareholding in the company within the next 6 months with a planned investment of no less than RMB 75 million and no more than RMB 150 million [1] - The share purchase will be executed based on Fangda Iron and Steel's reasonable judgment of the company's stock price, market fluctuations, and overall capital market trends [1] - The funding for the share purchase will come from Fangda Iron and Steel's own funds and special loans [2]

Summary of Conference Call Notes Company and Industry Overview - The conference call primarily discusses **Ding Sheng Tai Yuan**, a biotechnology company focused on **cell therapy** and **tumor treatment**. The company was established in **2014** and has a workforce of **153 employees**, with over **80%** being technical staff, indicating a highly educated and youthful team [6][7]. Key Points and Arguments Tumor Treatment and Immunotherapy - The discussion highlights the importance of the **immune system** in identifying and eliminating mutated cells that could lead to diseases like cancer. The **PCR (Polymerase Chain Reaction)** plays a crucial role in this immune monitoring process [2][3]. - Approximately **20%** of individuals may develop tumors at some point, often due to the failure of the immune system to monitor these mutations effectively [3]. - The **TCR (T Cell Receptor)** is emphasized as vital in tumor treatment, with its diversity reaching between **10^15** and **10^18** [3]. - The company aims to utilize **gene engineering** to enhance the immune response against tumors by modifying T cells to recognize and attack cancer cells [4][6]. Competitive Advantages - Ding Sheng Tai Yuan's competitive edge lies in its **technology platform**, which allows for the discovery and transformation of various tumor-targeting sequences into therapeutic products [7][8]. - The company has established collaborations with prestigious institutions like **301 Hospital** and **Tsinghua University** for clinical research, enhancing its credibility and research capabilities [8]. Product Pipeline and Market Potential - The company is developing innovative products, including **1102**, which targets the **KRAS G12D** mutation, prevalent in various cancers. In China, this mutation occurs in **45%** of colorectal cancer cases [14][15]. - The market potential for the targeted therapies is significant, with estimates suggesting a market size of **500 billion** for certain products and **100 billion** for others [17]. - The company is also exploring **CAR-T** therapies, which have shown promise in treating hematological malignancies but face challenges in solid tumors due to tumor heterogeneity [12]. Challenges and Future Outlook - The high cost of cell therapies, such as the **PCR-T** treatment priced over **$700,000**, poses a barrier to accessibility. The company is exploring ways to reduce costs through economies of scale and improved supply chain management [11][30][33]. - The company acknowledges the need for innovation in treatment modalities, particularly in the context of emerging therapies like **MHC** and **ADC** [18][19]. - The management expresses confidence in the future of cell therapy as a viable solution for cancer treatment, emphasizing the potential for breakthroughs in this field [22][23]. Additional Important Insights - The company is strategically positioned to leverage its traditional pharmaceutical background while transitioning into innovative therapies, aiming to become a leader in the cell therapy market [23][24]. - The collaboration with **Northeast Pharmaceutical** is seen as a strategic move to enhance capabilities in drug development and commercialization [26][27]. - The management emphasizes the importance of a robust clinical resource network to support the development and deployment of new therapies [41]. This summary encapsulates the key discussions and insights from the conference call, highlighting the company's strategic direction, competitive advantages, and the broader context of the biotechnology industry focused on cancer treatment.

Group 1: Production and Operational Strategies - The fourth quarter is crucial for setting annual goals and ensuring a strong start for the following year, with a focus on optimizing production processes and reducing costs while maintaining safety and quality standards [2] - The company aims to enhance production efficiency through measures such as improving product yield and reducing energy consumption [2] Group 2: Research and Development Progress - In 2023, the company launched 4 new products that received market approval, with an additional 4 products currently in review and clinical trial phases [3] - The company emphasizes a strong R&D foundation in areas such as oncology, anti-infection, metabolic diseases, reproductive systems, and nervous systems [3] Group 3: Competitive Advantages of DCTY1102 - DCTY1102 injection has a higher patient coverage potential in China, with the applicable HLA type (HLA-A*11:01) present in approximately 20% of the population, compared to only 0.3% for the competitor's product [7] - The company has developed a unique TCR technology platform that allows for personalized treatment and the development of cell and protein drugs targeting known and unknown tumor sites [3][7] Group 4: Clinical Trial and Regulatory Strategy - DCTY1102 is positioned to leverage orphan drug status for expedited registration processes, aiming to shorten the time to market while ensuring high-quality evaluations [5] - The company is actively designing clinical trials to enhance the efficiency of the review process and improve overall approval timelines [5] Group 5: Technical Advantages of TCR Protein Drugs - The company has achieved a significant increase in TCR affinity from micromolar to nanomolar levels, enhancing the recognition capability of TCR protein drugs [5] - The TCR protein drugs are designed to be soluble and stable, which is critical for their therapeutic effectiveness [5]

证券代码：000597 证券简称：东北制药 公告编号：2024-066 近日，东北制药集团股份有限公司（以下简称"东北制药/公司"）收到中华 人民共和国最高人民法院（以下简称"最高院"）民事裁定书（2024）最高法民 申 5558 号，驳回再审申请人（一审原告、反诉被告，二审上诉人)辽宁亿华实业 有限公司（以下简称"亿华公司"）、再审申请人（一审被告、反诉原告，二审 上诉人）东北制药就债权转让合同纠纷一案（以下简称"本案"）的再审申请。 本案具体内容详见公司分别于 2018 年 11 月 27 日、2022 年 11 月 28 日、2024 年 4 月 12 日、2024 年 11 月 2 日披露于巨潮资讯网的《东北制药集团股份有限公 司重大诉讼公告》（公告编号：2018-088）《东北制药集团股份有限公司重大诉 讼进展公告》（公告编号：2022-080）《东北制药集团股份有限公司重大诉讼进 展公告》（公告编号：2024-023）及《东北制药集团股份有限公司诉讼进展公告》 （公告编号：2024-062）的相关内容。 二、诉讼事项的进展情况 亿华公司与东北制药、抚顺县工业和信息化局债权转让合同纠纷一案,再审申 ...

东北制药集团股份有限公司 证券代码：000597 证券简称：东北制药 公告编号：2024-065 关于收购北京鼎成肽源生物技术有限公司 70%的股权进展 暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、交易概述 东北制药集团股份有限公司（以下简称"公司"）于 2024 年 8 月 6 日披露 了《东北制药集团股份有限公司关于签署股权收购框架协议的公告》（公告编号： 2024-047），拟收购北京鼎成肽源生物技术有限公司（以下简称"鼎成肽源"） 70%的股权。公司于 2024 年 11 月 5 日召开第九届董事会第三十三次会议，以同 意 11 票、反对 0 票、弃权 0 票审议通过了关于签署《股权收购协议》的议案， 并于 2024 年 11 月 6 日披露了《东北制药集团股份有限公司关于签署股权收购协 议的公告》（公告编号：2024-064）。 二、进展情况 近日，鼎成肽源已办理完成上述股权变更的相关备案核准手续，并已取得北 京市昌平区市场监督管理局登记通知书及营业执照。至此，鼎成肽源成为公司的 控股子公司并纳入公司合并报表范围。 ...

Core Insights - Northeast Pharmaceutical has signed a cash acquisition agreement to purchase 70% of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately 187 million yuan, marking a strategic entry into the specific cell immunotherapy sector [1][2] - Dingcheng Peptide Source, established in 2014, has developed a robust core technology platform for TCR-T, TCR protein drugs, and CAR-T cell therapy products, focusing on solid tumor cell treatment [1][2] Group 1: Acquisition Details - The acquisition allows Northeast Pharmaceutical to quickly enter the specific cell immunotherapy market, which is a rapidly evolving area in the pharmaceutical industry [1] - Dingcheng Peptide Source has developed over ten cell therapy products targeting various cancers, including pancreatic cancer and colorectal cancer, with a focus on specific mutations [2] Group 2: Product Pipeline and Future Prospects - The company has received clinical trial approval for its DCTY1102 injection, which is expected to be the first TCR-T cell drug targeting KRASG12D to enter Phase I clinical research in China [2] - Northeast Pharmaceutical views this acquisition as a significant opportunity to leverage Dingcheng Peptide Source's research capabilities and mature development team to enhance its position in the biopharmaceutical sector [3]